Assembly Biosciences, Inc. - Common Stock (ASMB)

Assembly Biosciences (ASMB) exemplifies a high-growth momentum stock, meeting strict technical uptrend criteria and showing accelerating earnings and sales fundamentals.

Assembly Biosciences (ASMB) stock meets Mark Minervini's Trend Template with a perfect technical rating, 397% from lows, and accelerating 298% revenue growth.

Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week technical strength and strong price action.

Assembly Biosciences reported interim results from its Phase 1a study of ABI-5366, a long-acting HSV inhibitor for recurrent genital herpes. The drug showed a favorable safety profile and achieved target plasma concentrations for antiviral efficacy.

ASMB stock results show that Assembly Biosciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

ASMB stock results show that Assembly Biosciences beat analyst estimates for earnings per share the first quarter of 2024.

ASMB stock results show that Assembly Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023.

ASMB stock results show that Assembly Biosciences missed analyst estimates for earnings per share the second quarter of 2023.

Shares of Icosavax, Inc. (NASDAQ: ICVX) rose sharply in pre-market trading after AstraZeneca announced plans to buy Icosavax in a deal valued at up to $1.1 billion.

U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite falling around 50 points on Tuesday. The Dow traded down 0.09% to 33,954.39 while the NASDAQ fell 0.37% to 13,517.59. The S&P 500 also fell, dropping, 0.10% to 4,369.41.

Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc.